Naltrexone is a non-toxic drug that blocks the effects of chemicals called opioids (examples: codeine, morphine, oxycodone), and is approved as a treatment for alcoholism. Naltrexone has been used in low doses by Dr. Bernard Bihari (a physician in New York) for treatment of various cancers with over a 60% response, and many remissions.

LDN works by boosting the level of natural opioids in the body called endorphins. One of the endorphins, OGF (also called met-enkephalin), has been shown to have a broad spectrum of anti-cancer effects including cell growth inhibition and stimulation of anti-cancer immune response. It has been discovered that many cancers respond to increased levels of OGF, and their growth can be stopped. A human study of OGF in pancreatic cancer showed complete disappearance of liver metastases in 2 out of 16 patients, and an estimated doubling of survival. Another study shows that OGF can enhance the effects of chemotherapy. Patients taking opiate pain killers cannot take LDN (with a few exceptions).

We are also now offering Enhanced LDN Therapy by combining LDN with an immune modulating drug called imiquimod. New research has shown that imiquimod can increase the sensitivity of cancer cells to OGF by increasing the number of OGF receptors. The potential benefit of this combined treatment is a stronger anti-cancer effect compared to LDN alone. Click for details about Medicor’s LDN treatment program, and to read some exciting case reports.

Medicor was also offering direct treatment with OGF to patients who were unable to take LDN due to regular use of pain medication. OGF availability can no longer be guaranteed. As a result, our OGF treatment program has been suspended indefinitely.